Richmond Pharmacology is the largest Early Phase CRO in the UK.
We are the only Early Phase CRO in the UK to conduct trials from within 2 acute NHS Teaching Hospitals. This gives us direct access to world leading professors and consultants, ensuring we offer our clients unparalleled expertise across a range of therapeutic areas.
We are based within two dedicated access-controlled facilities at St George's University London and Mayday Hospital.
Our spacious open plan wards have a 100 bed capacity.
We can provide immediate on site access to emergency care 24/7.
We host leading technology, designed to optimise every stage of the clinical trial process.
Our acute Phase I environment, in and out-patient facilities, leading technology and on-site therapeutic consultancy combine to offer a full service on any Early Phase study, from protocol to report. Our project managers are all life science graduates who provide you with a single point of contact to keep you updated on progress through each milestone.
We can undertake both the CRF design and protocol writing for any study we take on.
Your protocol will be written by a team of experts including the Medical Director, Project Management and our department of dedicated Medical Writers.
We can write and present the ethics submission and we attend ethics meetings to facilitate the approval process.
We can also write and submit the CTA application on behalf of our clients.
We have extensive experience with existing compounds and new chemical entities.
Single and multiple dose studies.
Measuring tolerability and safety, and a range of pharmacokinetic and pharmacodynamic assessments.
We maintain NHS crash trolleys in each of our wards, in addition to the direct access we have to the hospitals crash teams.
We have a long standing relationship with the Department of Cardiac and Vascular Sciences within St George's University London, led by Professor Camm, a world leading expert in this field.
Our dedicated MUSE system is networked to MAC 1200 12-lead ECG machines at every bed.
We offer our clients unparalleled cardiovascular expertise in the recording, manual interval measurement and analysis of ECGs.
We are Europe's largest provider of Japanese/Caucasian Bridging Studies.
Our unique recruitment ensures a large panel of both Caucasian and Japanese volunteers.
Our Japanese and Caucasian staff work together on all studies to ensure the understanding of Japanese culture and language, and most importantly to accurately document adverse events.
Our integrated trials centres and acute NHS surroundings provide the foundations for Early Phase patient studies.
We have access to a wide range of consultants and patient populations, all supported by our background in pharmacological proficiency.
We make use of the latest technology – Oracle Clinical Version 4.5.
Our experienced team delivers procedures to ensure consistent highest quality data within set timelines.
We produce fully integrated clinical reports, that are insightful and accurate.
Your report will be presented in data copy as well as a password protected file.
We have set up the largest dedicated volunteer recruitment department of any Early Phase CRO in the UK.
Our database grows at a rate of 1,000 new volunteers every month.
We have extensive experience in delivering panels of young, elderly, Caucasian and Japanese volunteers.
On-site access to consultants across 2 NHS teaching hospitals gives us access to patient populations in a number of therapeutic areas.
Our dedicated in house patient recruitment department coordinate recruitment both independently, through the consultants and via our trials4patients brand, promoted through nationwide marketing.
This combination of guaranteed volunteer panels, acute NHS surroundings and on-site therapeutic expertise enables Richmond Pharmacology to deliver full service Early Phase solutions swiftly, efficiently and to the highest clinical standard.